James Kost
YOU?
Author Swipe
View article: Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions
Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions Open
Background: Delay of progression from prodromal Alzheimer’s disease (AD) to dementia is an important outcome in AD trials. Centralized adjudication is intended to improve the consistency of dementia diagnosis but has not been scrutinized. …
View article: BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain Open
In the phase 3 EPOCH trial (Clinicaltrials.gov; NCT01739348), treatment with the BACE inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate Alzheimer’s disease, but was associated with reduced hippocampal vol…
View article: FTS3‐01‐05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE‐3 TRIAL OF VERUBECESTAT IN PRODROMAL AD
FTS3‐01‐05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE‐3 TRIAL OF VERUBECESTAT IN PRODROMAL AD Open
In the phase-3 APECS trial, the BACE inhibitor verubecestat failed to improve clinical outcomes in participants with prodromal AD and was associated with worsening on some measures, notably cognition. Worsening relative to placebo was appa…
View article: O3‐10‐02: VERUBECESTAT‐INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID‐ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE PATIENTS
O3‐10‐02: VERUBECESTAT‐INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID‐ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE PATIENTS Open
Treatment with BACE inhibitor verubecestat 12mg and 40mg failed to improve cognition in mild-to-moderate AD patients but was associated with reduced MRI brain volume on volumetric measures. To explore this observed effect, we performed kin…
View article: Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease Open
Verubecestat did not improve clinical ratings of dementia among patients with prodromal Alzheimer's disease, and some measures suggested that cognition and daily function were worse among patients who received verubecestat than among those…
View article: P4‐013: DESIGN OF A PHASE‐3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD
P4‐013: DESIGN OF A PHASE‐3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD Open
Verubecestat is a potent oral β-secretase (BACE) inhibitor that reduces Aβ levels by over 80% in cerebrospinal fluid (CSF) and brain of rodents and primates, as well as in the CSF of patients with AD. In a previous Phase-3 trial (EPOCH) ve…
View article: Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease Open
Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. (Funded by Merck; ClinicalTrials.gov number, NCT01739348 .).
View article: POTENTIAL THERAPEUTIC BENEFITS OF DECREASING Aβ PRODUCTION THROUGH BACE INHIBITION
POTENTIAL THERAPEUTIC BENEFITS OF DECREASING Aβ PRODUCTION THROUGH BACE INHIBITION Open
Alzheimer’s disease (AD) is a devastating global epidemic with economic and social burden. The amyloid hypothesis proposes that toxic aggregation of Aβ peptides, produced via cleavage of Amyloid Precursor Protein by β-secretase (BACE1) fol…